Leukaemia diagnoses range enormously in their urgency and their medical aid implications. An AML diagnosis may require hospitalisation within hours; a CML diagnosis, discovered incidentally on a blood test, allows days to weeks to sort out your medical aid before starting treatment. This guide addresses both scenarios with practical steps.
Your Immediate Protection
Leukaemia is a PMB condition. Your scheme must fund your diagnosis, staging, and treatment regardless of your plan or waiting periods. The questions from here are about which medicines are covered as PMB vs. exceptional needs, and whether your plan's oncology sub-limit is adequate for your treatment type.
Step 1: Acute or Chronic? The First Practical Question
If you have been diagnosed with AML or ALL (acute leukaemia): This is an oncological emergency. You may need to start induction chemotherapy within days. Contact your scheme's oncology case management line immediately — not after your first appointment, now. Ask for urgent pre-authorisation for hospital admission and induction chemotherapy.
Tell the case manager: "I have been diagnosed with acute leukaemia. My haematologist is recommending immediate hospitalisation for induction chemotherapy. This is urgent — I need authorisation today."
If you have been diagnosed with CML or CLL (chronic leukaemia): You have more time. But start the medical aid process within the week. The medication costs for CML (imatinib) and CLL (ibrutinib, venetoclax) are your primary financial concern, and the exceptional-needs process can take 1–2 weeks.
Step 2: Register with Oncology Case Management
For all leukaemia types:
- Call your scheme and ask specifically for oncology case management.
- Tell them your specific diagnosis (AML, ALL, CML, CLL).
- Request PMB oncology registration and a dedicated case manager.
Your case manager coordinates pre-authorisations, monitors your benefit usage, and serves as your point of escalation when claims are disputed.
Step 3: CML Patients — Confirm Imatinib Cover Immediately
If you have CML, your haematologist will prescribe imatinib (or a second-generation TKI if imatinib is not appropriate). Before you fill the prescription:
- Ask your case manager: "Is generic imatinib covered as my PMB chronic medication for CML, and what is the scheme's approved daily dose?"
- Confirm whether you need to enrol on the scheme's CDL (Chronic Disease List) programme — note: CML is NOT on the CDL, but many schemes register it as a chronic medicine benefit. Ask your case manager which programme applies.
- Ask about BCR-ABL monitoring tests (PCR blood tests, done every 3 months) — confirm these are funded under your diagnostic/PMB benefit.
If your haematologist recommends a second-generation TKI (dasatinib, nilotinib) because of intolerance or specific BCR-ABL mutation status, the exceptional-needs application must be submitted with the genotyping result.
Step 4: AML/ALL Patients — Pre-Authorise the Full Treatment Course
Acute leukaemia treatment runs in phases: - Induction: Hospital-based, intensive, typically 4–6 weeks in hospital. - Consolidation: Further chemotherapy cycles, may be in-hospital or outpatient. - Maintenance (ALL): Oral chemotherapy (6-mercaptopurine + methotrexate) for 2+ years.
Ask your case manager to issue a blanket pre-authorisation covering the full induction phase — not a day-by-day authorisation. Your haematologist can provide the treatment protocol in writing. This prevents authorisation lapsing during a hospital stay.
For patients where bone marrow transplant is being considered as consolidation: begin the transplant access discussion with your case manager as soon as your haematologist raises it. Authorisation for allogeneic transplant takes time and requires donor matching coordination.
Step 5: Understand Your Oncology Sub-Limit
Ask your case manager for your annual oncology sub-limit.
- CML on generic imatinib: Annual medication cost is R40,000–R100,000. A plan with a R250,000 sub-limit is likely adequate as long as the medication is correctly classified as the PMB chronic benefit rather than drawn from the oncology sub-limit.
- AML induction: A single in-hospital induction admission costs R200,000–R350,000. A plan with a R200,000 sub-limit is completely inadequate. If your sub-limit is below R400,000, explore upgrading your plan option within your scheme before treatment starts.
- Allogeneic BMT: Costs R500,000–R900,000. Confirm PMB BMT coverage and DSP facility access before the transplant discussion becomes urgent.
Step 6: Should You Switch Plans?
CML patients: If you are stable on generic imatinib and your plan covers it as a chronic/PMB benefit, plan switching is usually not necessary. The key question is whether the scheme funds the medication correctly — not the plan tier.
AML/ALL patients: If your sub-limit is below R400,000 and you are facing induction + consolidation + possible transplant, moving to a higher-option plan within your scheme before treatment starts is worth exploring. Intra-scheme option changes do not trigger new waiting periods for the existing diagnosis.
Emergency Resources
CANSA (Cancer Association of SA): 0800 22 6622 (toll-free, weekdays) Leukaemia and Lymphoma SA: llsa.org.za (patient support and navigation) Council for Medical Schemes: 0861 123 267 | www.medicalschemes.co.za
What AURA Does Differently
AURA shows you which plans correctly fund imatinib as a PMB chronic benefit vs. drawing from the oncology sub-limit — a distinction that saves CML patients tens of thousands of rands per year.
Get help understanding your cover options →